Literature DB >> 10386218

Managing elderly people's osteoporosis. Why? Who? How?

A Juby1.   

Abstract

OBJECTIVE: To guide family physicians through assessment of why treating elderly people's osteoporosis is necessary, who to treat, and how to treat in a practical way. QUALITY OF EVIDENCE: Evidence of the efficacy of treatment for osteoporosis is shown by a reduced probability of fracture. This can be ascertained by direct evaluation for bisphosphonates, calcium, and calcitonin, or indirectly by ascertaining benefit to bone mineral density for hormone replacement therapy (HRT) and exercise. MAIN MESSAGE: Unless medically contraindicated, all elderly people should take supplementary vitamin D (800 IU/d) and calcium (1500 mg/d). Those with risk factors for osteoporosis (e.g., smoking, thinness, previous fracture when older than 50 years, fracture in first-degree relatives older than 50 years, and steroid use) should have a bone density measurement. Those meeting World Health Organization criteria for osteoporosis should also be treated with HRT or bisphosphonates or possibly with selective estrogen receptor modulators.
CONCLUSIONS: Good evidence indicates that adequate treatment of osteoporosis can prevent fractures and thus reduce associated morbidity and mortality among vulnerable elderly people. Because of the prevalence of osteoporosis, the onus falls on family physicians to be the front-line managers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386218      PMCID: PMC2328450     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  41 in total

1.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

2.  Risk factors for falls among elderly persons living in the community.

Authors:  M E Tinetti; M Speechley; S F Ginter
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

3.  Sunscreens suppress cutaneous vitamin D3 synthesis.

Authors:  L Y Matsuoka; L Ide; J Wortsman; J A MacLaughlin; M F Holick
Journal:  J Clin Endocrinol Metab       Date:  1987-06       Impact factor: 5.958

4.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

5.  Psychotropic drug use and the risk of hip fracture.

Authors:  W A Ray; M R Griffin; W Schaffner; D K Baugh; L J Melton
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

6.  An epidemiologic study of hip fracture in postmenopausal women.

Authors:  N Kreiger; J L Kelsey; T R Holford; T O'Connor
Journal:  Am J Epidemiol       Date:  1982-07       Impact factor: 4.897

7.  Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.

Authors:  B L Riggs; E Seeman; S F Hodgson; D R Taves; W M O'Fallon
Journal:  N Engl J Med       Date:  1982-02-25       Impact factor: 91.245

8.  Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin.

Authors:  A R Webb; L Kline; M F Holick
Journal:  J Clin Endocrinol Metab       Date:  1988-08       Impact factor: 5.958

9.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  I R Reid; A R King; C J Alexander; H K Ibbertson
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

10.  Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women.

Authors:  C Hassager; J Pødenphant; B J Riis; J S Johansen; J Jensen; C Christiansen
Journal:  Metabolism       Date:  1989-03       Impact factor: 8.694

View more
  1 in total

1.  [Diagnosing osteoporosis in primary care in Spain (ABOPAP 2000 study)].

Authors:  R Aragonès Forès; P Orozco López
Journal:  Aten Primaria       Date:  2002-10-15       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.